Using engineered tissues to create a small working simulacrum of a beating heart, researchers at GlaxoSmithKline and TARA Biosystems aim to predict how the body’s cardiovascular system responds to potential therapies.
TARA’s 3D “heart-on-a-chip” system was able to accurately replicate human drug responses, according to a study published in the journal Toxicological Sciences—something that’s been difficult to achieve with in vitro testing or animal models.
With cardiac toxicity affecting almost half of new medicine recalls, effective preclinical testing and safety assessments are essential, the two companies said.
To construct the tissues, TARA took induced pluripotent stem cells and cultivated them into cardiomyocytes, the muscle cells of the heart. By directing the cells’ differentiation and conditioning them with electrical fields over a period of weeks, researchers were able to build distinct tissues that mimic the contractions of the atria and ventricles, as well as their drug responses and gene expression. Their work was published earlier this year in Cell.
By measuring how strongly the engineered tissues contract when dosed with different drugs, the companies can get a sense of how potential therapies may affect a healthy human heart’s ability to pump blood to the body. Researchers also saw that the drugs acted along the same molecular pathways seen in human heart tissue.
Additionally, by using stem cells derived from certain patients, the platform could also be used to model different heart diseases, according to TARA.
Currently, GSK is applying a panel of drugs with known efficacy and toxicity profiles, in order to compare TARA’s platform with other preclinical drug screening methods. These include its responses to blood pressure medications, such as Procardia (nifedipine), Isuprel (isoproterenol) and Digox (digoxin), as well as drugs being studied in heart failure, like dobutamine and omecamtiv.
In January, TARA launched a drug discovery collaboration with Insilico Medicine, focused on cardiovascular disease and cardiac muscle aging. The two aim to combine Insilico’s AI-powered discovery engine with TARA’s tissue models for testing.
By: Conor Hale
Source: Fierce Biotech
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
